
    
      The total study duration from screening for a patient can be approximately up to 1 year,
      including a screening period of 2 weeks, double-blinded placebo controlled treatment period
      of 16 weeks, an open-labeled extension period of 36 weeks, and a follow-up period of 3 days.
    
  